Can argenx (ENXTBR:ARGX) Justify Its Price As New Board Appointments Shift Focus?

Board changes put argenx in focus

argenx (ENXTBR:ARGX) shares came into focus after the Extraordinary General Meeting of Shareholders approved the appointments of Thomas M. Brakel and Khurem Farooq as non-executive directors on the board.

The board appointments land at a time when argenx’s 1-day share price return declined 2.29% and the 30-day move is down 3.29%. However, the 90-day share price return of 6.91% and 1-year total shareholder return of 34.37% point to momentum still skewing positive over a longer stretch.

Compare argenx’s board-driven story with other healthcare names by scanning our hand picked 134 healthcare AI stocks that could be setting up for the next big move.

Following short-term weakness and the appointment of a new board, argenx now sits at a crossroads where some investors consider waiting for a deeper pullback, while others focus on what the current valuation already implies.

Most Popular Narrative: 22% Overvalued

argenx last closed at €835.80, while the most followed narrative, according to kapirey, places fair value nearer to €686.43, which frames the stock as trading ahead of that estimate and turns attention to what might still justify the premium.

👉 Profile: High-growth biotech compounding story 👉 Investment type:

• Growth + clinical optionality

• High volatility

👉 Core thesis:

• If VYVGART becomes a multi-indication platform drug, there could be significant upside

• If pipeline fails or pricing pressure intensifies, there is material downside risk

See why 2 investors see argenx as 22% overvalued.

Result: Fair Value of €686.43 (OVERVALUED)

Still, the argenx narrative could be knocked off course if VYVGART concentration becomes a concern or key late stage trials deliver weaker than expected data.

Find out about the key risks to this argenx narrative.

Another View on argenx’s Value

While the leading community narrative tags argenx as about 22% overvalued at €835.80 versus an estimated fair value of €686.43, the SWS DCF model points the other way. It flags the shares as trading at roughly 67.6% below an estimated future cash flow value of €2,583.49.

That gap leaves investors weighing two very different stories. One is grounded in near term earnings multiples and sentiment. The other leans on long run cash flows and assumes the current pipeline and profitability can support a much higher equity value. Which story do you think better fits your own risk tolerance and time horizon?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out argenx for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 174 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Conflicted by the split view on argenx and what it really implies for risk and reward today, you should move quickly, test the numbers, and stress test your own thesis against the 4 key rewards and 2 important warning signs.

Looking for more argenx investment ideas?

If argenx has your attention, do not stop here. Broaden your watchlist now so you are not chasing the next opportunity after it moves.

• Target resilient balance sheets by scanning the list of solid balance sheet and fundamentals (199 results) and focus on businesses with fewer financial weak spots.
• Hunt for mispriced quality through the 174 high quality undervalued stocks and see which candidates still trade below their assessed worth.
• Prioritise stability first by reviewing the 229 resilient stocks with low risk scores and concentrate on companies with more measured risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com